We predict that sustained 15-PGDH inhibition via injectable, cyclodextrin-derived microparticles will be a novel tolerated strategy to not only reduce fibrotic deposition and decrease morbidity and mortality in murine pulmonary fibrosis, but to also reduce the demands on the patient to comply with therapeutic dosing regimens, with clinical implications for a number of additional fibrotic conditions. Here, HPGD is linked to pulmonary fibrosis.